BR112015024659A2 - tratamento de diabetes mellitus por formulações de ação prolongada de insulinas - Google Patents
tratamento de diabetes mellitus por formulações de ação prolongada de insulinasInfo
- Publication number
- BR112015024659A2 BR112015024659A2 BR112015024659A BR112015024659A BR112015024659A2 BR 112015024659 A2 BR112015024659 A2 BR 112015024659A2 BR 112015024659 A BR112015024659 A BR 112015024659A BR 112015024659 A BR112015024659 A BR 112015024659A BR 112015024659 A2 BR112015024659 A2 BR 112015024659A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- diabetes mellitus
- long
- acting insulin
- insulin formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 108010092217 Long-Acting Insulin Proteins 0.000 title abstract 2
- 102000016261 Long-Acting Insulin Human genes 0.000 title abstract 2
- 229940100066 Long-acting insulin Drugs 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 108010057186 Insulin Glargine Proteins 0.000 abstract 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 abstract 2
- 229960002869 insulin glargine Drugs 0.000 abstract 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 230000000422 nocturnal effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
resumo patente de invenção: "tratamento de diabetes mellitus por formulações de ação prolongada de insulinas". a presente invenção refere-se a uma formulação farmacêutica aquosa para uso no tratamento de diabetes mellitus tipo i ou tipo ii, em que o tratamento reduz o risco de hipoglicemia noturna, sendo que a dita formulação compreende 200 a 1000 u/ml [equimolares a 200 a 1000 iu de insulina humana] de insulina glargina, com a condição que a concentração da dita formulação não seja 684 u/ml de insulina glargina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305432 | 2013-04-03 | ||
| EP13290188 | 2013-08-08 | ||
| EP13306412 | 2013-10-15 | ||
| PCT/EP2014/056498 WO2014161837A1 (en) | 2013-04-03 | 2014-04-01 | Treatment of diabetes mellitus by long–acting formulations of insulins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015024659A2 true BR112015024659A2 (pt) | 2017-07-18 |
| BR112015024659A8 BR112015024659A8 (pt) | 2019-12-17 |
Family
ID=50424243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015024659A BR112015024659A8 (pt) | 2013-04-03 | 2014-04-01 | formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10092513B2 (pt) |
| EP (2) | EP2983697B1 (pt) |
| JP (1) | JP6457484B2 (pt) |
| KR (2) | KR102180215B1 (pt) |
| CN (2) | CN105142661B (pt) |
| AU (1) | AU2014247167B2 (pt) |
| BR (1) | BR112015024659A8 (pt) |
| CA (1) | CA2907848A1 (pt) |
| CL (1) | CL2015002914A1 (pt) |
| DK (1) | DK2983697T3 (pt) |
| ES (1) | ES2709339T3 (pt) |
| HK (1) | HK1214520A1 (pt) |
| HU (1) | HUE042381T2 (pt) |
| IL (1) | IL240949B (pt) |
| MX (1) | MX369511B (pt) |
| MY (1) | MY181626A (pt) |
| PH (1) | PH12015501931A1 (pt) |
| RU (2) | RU2019133674A (pt) |
| SG (1) | SG11201506888VA (pt) |
| UA (1) | UA117480C2 (pt) |
| WO (1) | WO2014161837A1 (pt) |
| ZA (1) | ZA201506420B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| MY181626A (en) | 2013-04-03 | 2020-12-29 | Sanofi Sa | Treatment of diabetes mellitus by long-acting formulations of insulins |
| US20220202711A1 (en) * | 2013-04-03 | 2022-06-30 | Sanofi | Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| US11158413B2 (en) * | 2018-04-23 | 2021-10-26 | Medtronic Minimed, Inc. | Personalized closed loop medication delivery system that utilizes a digital twin of the patient |
| US11986629B2 (en) | 2019-06-11 | 2024-05-21 | Medtronic Minimed, Inc. | Personalized closed loop optimization systems and methods |
| WO2023250076A1 (en) * | 2022-06-23 | 2023-12-28 | Hygieia, Inc. | Systems and methods for identifying medical conditions or treatment issues using optimized diabetes patient management data |
| CN117558435B (zh) * | 2024-01-11 | 2024-03-19 | 四川省医学科学院·四川省人民医院 | 一种基于bcm设备的远程透析指导系统 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4153689A (en) | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
| US4165370A (en) | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| EP0083619A1 (en) | 1981-07-17 | 1983-07-20 | Nordisk Insulinlaboratorium | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
| DE3576120D1 (de) | 1984-06-09 | 1990-04-05 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung. |
| CA1274774A (en) | 1985-04-15 | 1990-10-02 | Kenneth S. Su | Method for administering insulin |
| US4960702A (en) | 1985-09-06 | 1990-10-02 | Codon | Methods for recovery of tissue plasminogen activator |
| PH23446A (en) | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| DE3936876A1 (de) | 1989-11-06 | 1991-05-23 | Hoechst Ag | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| CH682806A5 (de) | 1992-02-21 | 1993-11-30 | Medimpex Ets | Injektionsgerät. |
| CH682805A5 (de) | 1992-02-24 | 1993-11-30 | Medimpex Ets | Anzeigeeinrichtung für ein Injektionsgerät. |
| DK0748213T3 (da) | 1994-03-07 | 2004-08-02 | Nektar Therapeutics | Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| YU18596A (sh) | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
| AU752411B2 (en) | 1996-08-13 | 2002-09-19 | Genentech Inc. | Formulation |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| CO4750643A1 (es) | 1997-06-13 | 1999-03-31 | Lilly Co Eli | Formulacion estable de la insulina que contiene l-arginina y protamina |
| CA2306905A1 (en) | 1997-10-24 | 1999-05-06 | Eli Lilly And Company | Fatty acid-acylated insulin analogs |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CZ20011134A3 (cs) | 1998-10-16 | 2001-08-15 | Novo Nordisk A/S | Stabilní koncentrované insulinové přípravky pro plicní podávání |
| EP1140145B2 (en) | 1999-01-14 | 2019-05-15 | Amylin Pharmaceuticals, LLC | Novel exendin agonist formulations and methods of administration thereof |
| US6978471B1 (en) | 1999-05-25 | 2005-12-20 | Thomson Licensing S.A. | System for acquiring and processing broadcast programs and program guide data |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
| DK1326630T3 (da) | 2000-09-18 | 2008-09-15 | Sanos Bioscience As | Anvendelse af GLP-2-peptider |
| WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| US20030026872A1 (en) | 2001-05-11 | 2003-02-06 | The Procter & Gamble Co. | Compositions having enhanced aqueous solubility and methods of their preparation |
| US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| FR2827604B1 (fr) | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| WO2003020201A2 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| US20100069293A1 (en) | 2002-02-27 | 2010-03-18 | Pharmain Corporation | Polymeric carrier compositions for delivery of active agents, methods of making and using the same |
| US7115563B2 (en) | 2002-05-29 | 2006-10-03 | Insignion Holding Limited | Composition and its therapeutic use |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| WO2004005342A1 (en) | 2002-07-04 | 2004-01-15 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
| DE10235168A1 (de) | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
| GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| DE602004029630D1 (de) | 2003-03-04 | 2010-12-02 | Technology Dev Co Ltd | Injizierbare Insulinzubereitung mit Langzeitwirkung und Verfahren zur dessen Herstellung und Verwendung |
| WO2005020927A2 (en) | 2003-08-29 | 2005-03-10 | Centocor, Inc. | Method of promoting graft survival with anti-tissue factor antibodies |
| JP2007515235A (ja) | 2003-12-22 | 2007-06-14 | ノボ・ノルデイスク・エー／エス | 医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器 |
| EP1701714A2 (en) | 2004-01-07 | 2006-09-20 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
| US20080248999A1 (en) | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
| WO2005097175A2 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
| BRPI0519241A2 (pt) | 2004-12-22 | 2009-01-06 | Centocor Inc | agonistas, composiÇÕes, mÉtodos e usos de glp-1 |
| US7879361B2 (en) | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
| WO2007038540A1 (en) | 2005-09-26 | 2007-04-05 | Medtronic, Inc. | Prosthetic cardiac and venous valves |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| DK1940243T3 (da) | 2005-10-24 | 2011-11-14 | Nestec Sa | Kostfiberformulering og fremgangsmåde til indgivelse |
| AU2005338631B2 (en) | 2005-11-30 | 2011-12-01 | Generex Pharmaceuticals Inc. | Orally absorbed pharmaceutical formulation and method of administration |
| US20100029558A1 (en) | 2005-12-06 | 2010-02-04 | Bristow Cynthia L | Alpha1 proteinase inhibitor peptides methods and use |
| CN101454019A (zh) | 2006-04-12 | 2009-06-10 | 百达尔公司 | 速效和长效胰岛素联合制剂 |
| JP2009539778A (ja) | 2006-06-08 | 2009-11-19 | ダイアベコア メディカル インコーポレイテッド | インスリンオリゴマー誘導体 |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| JP2009544716A (ja) | 2006-07-27 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | 肺送達のためのインスリン含有エアロゾル化可能製剤 |
| EP2581441A1 (en) | 2007-08-09 | 2013-04-17 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
| ES2558930T3 (es) | 2007-08-13 | 2016-02-09 | Novo Nordisk A/S | Análogos de la insulina de acción rápida |
| PL2209800T3 (pl) | 2007-11-16 | 2013-12-31 | Novo Nordisk As | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
| JP5352596B2 (ja) | 2008-01-04 | 2013-11-27 | バイオデル， インコーポレイテッド | 組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤 |
| RU2495131C2 (ru) | 2008-02-19 | 2013-10-10 | Байокон Лимитид | Способ получения рекомбинантного инсулина гларгина |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| WO2009143014A1 (en) | 2008-05-23 | 2009-11-26 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist bioassays |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| WO2010028055A1 (en) | 2008-09-02 | 2010-03-11 | Biodel, Inc. | Insulin with a basal release profile |
| DE102008053048A1 (de) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
| HUE037449T2 (hu) | 2008-10-17 | 2018-08-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| MX2011004357A (es) | 2008-10-30 | 2011-05-23 | Novo Nordisk As | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario. |
| MX2011008416A (es) | 2009-02-13 | 2011-09-08 | Boehringer Ingelheim Int | Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos. |
| US8709400B2 (en) | 2009-07-27 | 2014-04-29 | Washington University | Inducement of organogenetic tolerance for pancreatic xenotransplant |
| RU2556340C2 (ru) | 2009-07-31 | 2015-07-10 | Санофи-Авентис Дойчланд Гмбх | Композиция инсулина длительного действия |
| AR080669A1 (es) | 2009-11-13 | 2012-05-02 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina |
| US20110118178A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| RS52629B2 (sr) | 2009-11-13 | 2019-11-29 | Sanofi Aventis Deutschland | Liksisenatid kao dodatna terapija insulin glarginu i metforminu za lečenje dijabetesa tipa 2 |
| WO2011058082A1 (de) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin |
| CN102933200B (zh) | 2009-12-18 | 2015-11-25 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
| US20130085101A1 (en) | 2010-02-22 | 2013-04-04 | Case Western Reserve University | Long-acting insulin analogue preparations in soluble and crystalline forms |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| UY33326A (es) | 2010-04-14 | 2011-12-01 | Sanofi Aventis | Conjugados de insulina-sirna |
| US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
| AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| WO2011144674A2 (en) | 2010-05-20 | 2011-11-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD |
| EP2389945A1 (en) * | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising AVE0010 and insulin glargine |
| US9085757B2 (en) | 2010-06-17 | 2015-07-21 | Regents Of The University Of Minnesota | Production of insulin producing cells |
| US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
| ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
| US20130261051A1 (en) | 2010-10-27 | 2013-10-03 | Thue Johansen | Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals |
| WO2012065996A1 (en) * | 2010-11-15 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN |
| WO2012066086A1 (en) | 2010-11-17 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN |
| TW201236692A (en) | 2011-02-02 | 2012-09-16 | Sanofi Aventis Deutschland | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| CA2852056C (en) | 2011-03-11 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
| EP2763691A1 (en) | 2011-10-04 | 2014-08-13 | Sanofi-Aventis Deutschland GmbH | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract |
| BR112014016889A8 (pt) | 2012-01-09 | 2017-07-04 | Adocia | composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8 |
| MY181626A (en) | 2013-04-03 | 2020-12-29 | Sanofi Sa | Treatment of diabetes mellitus by long-acting formulations of insulins |
-
2014
- 2014-04-01 MY MYPI2015702871A patent/MY181626A/en unknown
- 2014-04-01 SG SG11201506888VA patent/SG11201506888VA/en unknown
- 2014-04-01 BR BR112015024659A patent/BR112015024659A8/pt not_active Application Discontinuation
- 2014-04-01 CN CN201480020095.1A patent/CN105142661B/zh active Active
- 2014-04-01 WO PCT/EP2014/056498 patent/WO2014161837A1/en active Application Filing
- 2014-04-01 CA CA2907848A patent/CA2907848A1/en active Pending
- 2014-04-01 EP EP14714692.2A patent/EP2983697B1/en not_active Revoked
- 2014-04-01 KR KR1020157030317A patent/KR102180215B1/ko active IP Right Grant
- 2014-04-01 RU RU2019133674A patent/RU2019133674A/ru unknown
- 2014-04-01 AU AU2014247167A patent/AU2014247167B2/en active Active
- 2014-04-01 RU RU2015146982A patent/RU2705797C2/ru active
- 2014-04-01 EP EP18200119.8A patent/EP3517122A1/en active Pending
- 2014-04-01 ES ES14714692T patent/ES2709339T3/es active Active
- 2014-04-01 JP JP2016505794A patent/JP6457484B2/ja active Active
- 2014-04-01 DK DK14714692.2T patent/DK2983697T3/en active
- 2014-04-01 CN CN201910671101.4A patent/CN110354255B/zh active Active
- 2014-04-01 MX MX2015014007A patent/MX369511B/es active IP Right Grant
- 2014-04-01 HU HUE14714692A patent/HUE042381T2/hu unknown
- 2014-04-01 UA UAA201510619A patent/UA117480C2/uk unknown
- 2014-04-01 KR KR1020207032526A patent/KR20200130511A/ko not_active IP Right Cessation
- 2014-04-01 US US14/781,857 patent/US10092513B2/en active Active
-
2015
- 2015-08-31 IL IL240949A patent/IL240949B/en active IP Right Grant
- 2015-09-01 ZA ZA2015/06420A patent/ZA201506420B/en unknown
- 2015-09-02 PH PH12015501931A patent/PH12015501931A1/en unknown
- 2015-09-30 CL CL2015002914A patent/CL2015002914A1/es unknown
-
2016
- 2016-03-07 HK HK16102529.8A patent/HK1214520A1/zh unknown
-
2018
- 2018-08-30 US US16/117,310 patent/US20190060233A1/en not_active Abandoned
-
2019
- 2019-12-02 US US16/700,541 patent/US11191722B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015024659A2 (pt) | tratamento de diabetes mellitus por formulações de ação prolongada de insulinas | |
| PH12019500517A1 (en) | Long-acting formulations of insulins | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| BR112014006684A2 (pt) | análogos de glucagon | |
| BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| CL2015002940A1 (es) | Usos terapéuticos de empaglifozina. | |
| BR112015013809A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
| BR112012017054A2 (pt) | "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" | |
| BR112014023374A2 (pt) | composições de peptídeos de glp-1 e preparação das mesmas | |
| CL2013000716A1 (es) | Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2. | |
| BR112014004726A2 (pt) | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 | |
| BR112013004756B1 (pt) | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 | |
| BR112013019744A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 | |
| BR112014010590A2 (pt) | 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose | |
| BR112013029269A8 (pt) | combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2 | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| BR112013001301A2 (pt) | processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana | |
| EA201201617A1 (ru) | Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| TH172399A (th) | การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |